Se connecter

Bibliographies thématiques / NK cell therapy

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « NK cell therapy »

Auteur : Grafiati

Publié le 9 mars 2023

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « NK cell therapy ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "NK cell therapy"

1

Qiao, Wenhua, Peng Dong, Hui Chen, and Jianmin Zhang. "Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy." Cells 13, no. 23 (2024): 1976. http://dx.doi.org/10.3390/cells13231976.

Texte intégral

Résumé :

Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system capable of killing virus-infected cells and/or cancer cells. The commonly used NK cells for therapeutic applications include primary NK cells and immortalized NK cell lines. However, primary NK cell therapy faces limitations due to its restricted proliferation capacity and challenges in stable storage. Meanwhile, the immortalized NK-92 cell line requires irradiation prior to infusion, which reduces its cytotoxic activity, providing a ready-made alternative and overcoming these bottlenecks. Recent improvements in di

Styles APA, Harvard, Vancouver, ISO, etc.

2

Wang, Hua, Bi-bo Fu, Robert Peter Gale, and Yang Liang. "NK-/T-cell lymphomas." Leukemia 35, no. 9 (2021): 2460–68. http://dx.doi.org/10.1038/s41375-021-01313-2.

Texte intégral

Résumé :

AbstractNatural killer/T-cell lymphoma (NKTL) is a sub-type of Epstein–Barr virus (EBV)-related non-Hodgkin lymphomas common in Asia and Latin America but rare elsewhere. Its pathogenesis is complex and incompletely understood. Lymphoma cells are transformed from NK- or T-cells, sometimes both. EBV-infection and subsequent genetic alterations in infected cells are central to NKTL development. Hemophagocytic syndrome is a common complication. Accurate staging is important to predict outcomes but there is controversy which system is best. More than two-thirds of NKTL lympohmas are localized at d

Styles APA, Harvard, Vancouver, ISO, etc.

3

Lachota, Mieszko, Marianna Vincenti, Magdalena Winiarska, Kjetil Boye, Radosław Zagożdżon, and Karl-Johan Malmberg. "Prospects for NK Cell Therapy of Sarcoma." Cancers 12, no. 12 (2020): 3719. http://dx.doi.org/10.3390/cancers12123719.

Texte intégral

Résumé :

Natural killer (NK) cells are innate lymphoid cells with potent antitumor activity. One of the most NK cell cytotoxicity-sensitive tumor types is sarcoma, an aggressive mesenchyme-derived neoplasm. While a combination of radical surgery and radio- and chemotherapy can successfully control local disease, patients with advanced sarcomas remain refractory to current treatment regimens, calling for novel therapeutic strategies. There is accumulating evidence for NK cell-mediated immunosurveillance of sarcoma cells during all stages of the disease, highlighting the potential of using NK cells as a

Styles APA, Harvard, Vancouver, ISO, etc.

4

Hurton, Lenka, R. Iram Siddik, Harjeet Singh, et al. "Identifying NK-Cell Donors for Cell Therapy Based on Functional Phenotype." Blood 110, no. 11 (2007): 3271. http://dx.doi.org/10.1182/blood.v110.11.3271.3271.

Texte intégral

Résumé :

Abstract Donor natural killer (NK) cells after haploidentical hematopoietic stem-cell transplantation (HSCT) and infusion of haploidentical NK-cells have demonstrated a therapeutic effect. NK alloreactivity resulting from appropriate Killer cell Ig-like receptor (KIR)-ligand disparity in human-leukocyte-antigen (HLA)-haplotype mismatched HSCT has resulted in improved engraftment and decreased incidence of leukemia relapse. Yet, not all patient-donor pairs benefit for an allogeneic NK-cell effect. To identify NK-cell donors with a suitable KIR-ligand mismatch, we have developed a functional ass

Styles APA, Harvard, Vancouver, ISO, etc.

5

Parameswaran, Reshmi, David N. Wald, Marcos De Lima, Dean A. Lee, and Stephen Moreton. "Novel Approach for NK Cell Therapy for Cancer." Blood 124, no. 21 (2014): 3836. http://dx.doi.org/10.1182/blood.v124.21.3836.3836.

Texte intégral

Résumé :

Abstract Novel therapeutic approaches are urgently needed for many malignancies such as Acute Myeloid Leukemia (AML). We have developed a new therapeutic strategy based upon NK cell immunotherapy that exhibits high clinical potential based upon cell and animal studies. While the harnessing of NK cells for cellular therapy against malignancies has been a topic of interest for several decades, our approach overcomes a major hurdle of insufficient NK cell cytotoxic activity. We have identified that targeting the kinase GSK3 through pharmacologic and genetic approaches leads to the hyperactivation

Styles APA, Harvard, Vancouver, ISO, etc.

6

Chu, Yaya, Margaret Lamb, Mitchell S. Cairo, and Dean A. Lee. "The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)." Current Treatment Options in Oncology 23, no. 3 (2022): 381–403. http://dx.doi.org/10.1007/s11864-021-00932-2.

Texte intégral

Résumé :

Opinion statementNatural killer (NK) cells have played a critical—if largely unrecognized or ignored—role in the treatment of B cell non-Hodgkin lymphoma (NHL) since the introduction of CD20-directed immunotherapy with rituximab as a cornerstone of therapy over 25 years ago. Engagement with NK cells leading to lysis of NHL targets through antibody-dependent cellular cytotoxicity (ADCC) is a critical component of rituximab’s mechanism of action. Despite this important role, the only aspect of B cell NHL therapy that has been adopted as standard therapy that even indirectly augments or restores

Styles APA, Harvard, Vancouver, ISO, etc.

7

Lyu, Jiaying. "Car-NK cell therapy for overcoming solid tumors." Highlights in Science, Engineering and Technology 36 (March 21, 2023): 1078–82. http://dx.doi.org/10.54097/hset.v36i.6177.

Texte intégral

Résumé :

There are many standard treatments for solid tumors, including surgery, chemotherapy, radiotherapy, or combination therapy, but all of them are difficult to maintain long-term anti-cancer effects. Recent immunotherapies such as Car-T have achieved remarkable results in hematologic cancers. However, clinical success of immunotherapy for solid tumors remains difficult to achieve due to the specific nature of solid tumor microenvironment and impediments to drug delivery. NK cell therapies can be divided into two main types, those that directly use unmodified NK cells to kill cancer cells and CAR-

Styles APA, Harvard, Vancouver, ISO, etc.

8

Valamehr, Bahram. "Advancing iPSC-derived NK cell therapy." Cell and Gene Therapy Insights 5, no. 12 (2019): 1655–61. http://dx.doi.org/10.18609/cgti.2019.173.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Mehta, Rohtesh S., Brion Randolph, May Daher, and Katayoun Rezvani. "NK cell therapy for hematologic malignancies." International Journal of Hematology 107, no. 3 (2018): 262–70. http://dx.doi.org/10.1007/s12185-018-2407-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Stoltzman, Carrie, Devikha Chandrasekaran, Erika von Euw, Cyd McKay, Christina Root, and Colleen Delaney. "Abstract 2 Development of CAR-NK Cell Therapy for Hematologic Malignancies." Stem Cells Translational Medicine 11, Supplement_1 (2022): S4. http://dx.doi.org/10.1093/stcltm/szac057.002.

Texte intégral

Résumé :

Abstract Introduction Natural killer (NK) cells can kill tumor cells without priming or prior activation through their complement of activating and inhibitory surface molecules. Chimeric antigen receptor (CAR) expression by engineered NK cells can improve both specificity and potency of the NK cells’ anti-tumor efficacy. CAR-NK cell therapy may be a safer, more clinically accessible, and cost effective allogeneic cellular therapy in comparison to autologous CAR-T cell therapy, as NK cells do not cause graft versus host disease (GvHD) or cytokine release syndrome (CRS). Objective We aimed to de

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "NK cell therapy"

1

Jaime-Ramirez, Alena Cristina. "HER2 and Folate Receptor Targeted Therapy is Enhanced by NK Cell-Activating Cytokines." The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1364465780.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Ojo, Evelyn. "Approaches to Improve the Proliferation and Activity of Natural Killer Cells for Adoptive Cell Therapy." Case Western Reserve University School of Graduate Studies / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=case1536760957918928.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Wang, Siao-Yi. "Interactions between complement and cellular mediated mechanisms of monoclonal antibody therapy." Diss., University of Iowa, 2010. https://ir.uiowa.edu/etd/619.

Texte intégral

Résumé :

Monoclonal antibodies (mAbs) have become an important part of therapy for a number of cancers. The first mAb to be approved for clinical use is rituximab, which is currently used for the treatment of various B cell malignancies. Despite its clinical value, the mechanisms in which rituximab induces tumor regression are unclear. Growing evidence suggests that multiple mechanisms involving complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) are involved. However, the direct interactions between CDC and ADCC have yet to be investigated. My studies examine th

Styles APA, Harvard, Vancouver, ISO, etc.

4

Suck, Garnet, Yeh Ching Linn, and Torsten Tonn. "Natural Killer Cells for Therapy of Leukemia." Karger, 2016. https://tud.qucosa.de/id/qucosa%3A71644.

Texte intégral

Résumé :

Clinical application of natural killer (NK) cells against leukemia is an area of intense investigation. In human leukocyte antigen-mismatched allogeneic hematopoietic stem cell transplantations (HSCT), alloreactive NK cells exert powerful anti-leukemic activity in preventing relapse in the absence of graft-versus-host disease, particularly in acute myeloid leukemia patients. Adoptive transfer of donor NK cells post-HSCT or in non-transplant scenarios may be superior to the currently widely used unmanipulated donor lymphocyte infusion. This concept could be further improved through transfusion

Styles APA, Harvard, Vancouver, ISO, etc.

5

Ewen, Eva-Maria [Verfasser], and Viktor [Akademischer Betreuer] Umansky. "Pro-inflammatory cytokines unleash natural killer cell potential for tumor therapy : NK cells want to break free / Eva-Maria Ewen ; Betreuer: Viktor Umansky." Heidelberg : Universitätsbibliothek Heidelberg, 2019. http://d-nb.info/1180394402/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

RAMBALDI, BENEDETTA. "Understanding T and NK cell reconstitution after allogeneic hematopoietic cell transplantation: a path to improve graft versus leukemia and minimize graft versus host disease." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2023. https://hdl.handle.net/10281/402375.

Texte intégral

Résumé :

Il trapianto di cellule ematopoietiche (HCT) rappresenta una terapia cardine per il trattamento delle neoplasie ematologiche altrimenti incurabili. Tuttavia, la procedura di trapianto può essere gravata dalla recidiva della malattia, dalla malattia del trapianto contro l'ospite (GVHD) e dalle infezioni. Le cellule T e NK che ricostituiscono dopo l'HCT proteggono da infezioni e recidive, ma sono anche coinvolte nella patogenesi della GVHD. Gli obiettivi del mio progetto di dottorato erano di migliorare la comprensione della ricostituzione delle cellule T e NK, utilizzando campioni di donatori s

Styles APA, Harvard, Vancouver, ISO, etc.

7

Kübler, Ayline [Verfasser], and Rupert [Akademischer Betreuer] Handgretinger. "Optimization of NK cell-based immune therapy strategies against pediatric acute B cell precursor leukemia using a human-murine xenotransplantation model / Ayline Kübler ; Betreuer: Rupert Handgretinger." Tübingen : Universitätsbibliothek Tübingen, 2015. http://d-nb.info/1163664618/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Craperi, Delphine. "Thérapie génique des gliomes : caractérisation des voies cytotoxiques déclenchées par le système thymidine kinase herpétique/ganciclovir." Université Joseph Fourier (Grenoble ; 1971-2015), 1998. http://www.theses.fr/1998GRE10073.

Texte intégral

Résumé :

La therapie genique par transfert du gene de la thymidine kinase du virus de l'herpes simplex de type 1 (hsv1-tk) suivi d'un traitement avec la prodrogue ganciclovir (gcv) a ete utilisee pour le traitement de divers cancers. L'efficacite de cette therapie est en partie due a l'existence d'un effet de toxicite de voisinage : le traitement au ganciclovir entraine non seulement la mort des cellules exprimant hsv1-tk mais aussi celle des cellules adjacentes non transfectees. Nous avons entrepris une etude in vitro des mecanismes moleculaires de la toxicite de ce systeme enzyme/prodrogue sur des li

Styles APA, Harvard, Vancouver, ISO, etc.

9

GUOLO, FABIO. "POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA PATIENTS: A SAFE AND EFFECTIVE THERAPY ASSOCIATED WITH EXPANSION AND MATURATION OF NK CELLS." Doctoral thesis, Università degli studi di Genova, 2021. http://hdl.handle.net/11567/1043790.

Texte intégral

Résumé :

Hodgkin Lymphoma (HL) is a B-Cell neoplasia with a favourable outcome in responding patients. However, despite the efficacy of first line therapy about 30% of patients eventually relapse or are refractory (R/R). Recently, the immune checkpoint inhibitor (CI) nivolumab demonstrated good activity in R/R HL patients although the complete response (CR) rate was less than 20%. The efficacy of nivolumab is strictly related to the host degree of immune competence, which is greatly impaired in heavily pre-treated HL patients after autologous stem cell transplantation (ASCT). To enhance the activity of

Styles APA, Harvard, Vancouver, ISO, etc.

10

Oh, Jun Seok. "Critical Roles of Cytomegalovirus-Induced Natural Killer Cells in Chronic Hepatitis C Virus Infection and Rituximab-Mediated Cancer Therapy." Thesis, Université d'Ottawa / University of Ottawa, 2017. http://hdl.handle.net/10393/36228.

Texte intégral

Résumé :

Natural Killer (NK) cells, members of the innate lymphoid cells (ILCs), are known to play an important role in the defense against foreign cells and abnormal host cells that have arisen due to viral infection or cancer inducing mutations. The typical immune response of NK cells involves the release of cytotoxic granules containing perforin and granzyme, and the secretion of immune-regulatory cytokines such as interferon gamma (IFN-γ). Unlike the adaptive lymphocytes such as T cells and B cells, NK cells do not require prior sensitization, enabling them to initiate an immune response much faste

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "NK cell therapy"

1

Schatt, Stephan. An animal model for in utero HSC transplantation and the role of cytokine secretion by T- and NK cells in pregnancy /von Stephan Schatt. Schatt, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "NK cell therapy"

1

Lee, Dean Anthony, Laurence James Neil Cooper, and Elizabeth J. Shpall. "NK-Cell Immunotherapy for AML." In Targeted Therapy of Acute Myeloid Leukemia. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1393-0_40.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Henkart, Pierre A. "Mechanism of NK-cell mediated cytotoxicity." In Cancer Immunology: Innovative Approaches to Therapy. Springer US, 1986. http://dx.doi.org/10.1007/978-1-4613-2629-8_4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Oguchi, Masahiko. "Extranodal NK/T Cell Lymphoma, Nasal Type." In Radiation Therapy for Extranodal Lymphomas. Springer Japan, 2017. http://dx.doi.org/10.1007/978-4-431-56435-5_3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Li, Yexiong. "Extranodal NK/T-Cell Lymphoma, Nasal Type." In Radiation Therapy in Hematologic Malignancies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-42615-0_11.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Lee, Dean Anthony, Laurence James Neil Cooper, and Elizabeth J. Shpall. "Erratum to: NK-Cell Immunotherapy for AML." In Targeted Therapy of Acute Myeloid Leukemia. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-1393-0_44.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Hu, Jinqiao. "CAR-NK Cell Therapy: A Promising Alternative to CAR-T Cell Therapy." In Proceedings of the 2022 6th International Seminar on Education, Management and Social Sciences (ISEMSS 2022). Atlantis Press SARL, 2022. http://dx.doi.org/10.2991/978-2-494069-31-2_48.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Nerina, Denaro, and Marco Carlo Merlano. "NK Cells in Immunotherapy: How Important Are They?" In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_5.

Texte intégral

Résumé :

AbstractNK cells are able to perform multiple functions, ranging from immunosurveillance to elimination of mutated or damaged cells, through many different cytotoxic mechanisms. Their functions can be very useful for cancer immunotherapy. But to achieve the maximum support from these extraordinary cells it is necessary to know their effector mechanisms and the mechanisms that lead to their suppression. We have briefly summarized some interesting aspect of their role in immunosurveillance of cancer and metastases, the major mechanisms of cell cytotoxicity, in particular their role in antigen de

Styles APA, Harvard, Vancouver, ISO, etc.

8

Multhoff, G., E. A. Repasky, and Peter Vaupel. "Mild Hyperthermia Induced by Water-Filtered Infrared A Irradiation: A Potent Strategy to Foster Immune Recognition and Anti-Tumor Immune Responses in Superficial Cancers?" In Water-filtered Infrared A (wIRA) Irradiation. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92880-3_10.

Texte intégral

Résumé :

AbstractApart from a number of positive “physiological” effects such as an increase in local blood flow which results in an improved oxygen supply and a reversal of tumor hypoxia, a key hallmark of cancer growth which greatly impairs anti-tumor immune responses, hyperthermia (HT) also exerts beneficial effects on anti-cancer immunity. The water-filtered infrared A (wIRA) irradiation technique achieves tissue temperatures in the fever-range (tT = 39–41 °C) or mild hyperthermia levels (tT = 39–43 °C) up to tissue depths of ≈25 mm in tissues. At tissue temperatures of 39–43 °C, by fostering the r

Styles APA, Harvard, Vancouver, ISO, etc.

9

Whiteside, T. L., N. L. Vujanovic, and R. B. Herberman. "Natural Killer Cells and Tumor Therapy." In Specificity, Function, and Development of NK Cells. Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-46859-9_13.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Chu, Yaya, Allyson Flower, and Mitchell S. Cairo. "Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy." In Natural Killer Cells. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3684-7_18.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "NK cell therapy"

1

Tent, Michiel. "Allogeneic CD19-targeting CAR NK-cell therapy for SLE." In ACR Convergence 2024, edited by Dennis McGonagle. Medicom Medical Publishers, 2025. https://doi.org/10.55788/cb70d4ab.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Cichocki, Frank, Barham Valamehr, Ryan Bjordahl, et al. "Abstract 3752: FATE-NK100: A novel NK cell-mediated cancer therapy." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3752.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Chang, Jae Woong, Joshua Krueger, Young Vue, et al. "247 Armored mesothelin CAR-NK cell therapy for advanced ovarian cancer." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0247.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Wu, Jennifer, Payal Dhar, Sizhe Liu, and Karla Guerra. "425 Antibody targeting tumor-derived soluble MIC reprograms NK cell metabolic fitness and enhances NK cell-based therapy for solid tumors." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0425.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Bergantini, Laura, Miriana D'Alessandro, Tommaso Pianigiani, Elena Bargagli, and Paolo Cameli. "NK cell maturation and proliferation in severe asthmatic patients after Benralizumab therapy." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.oa4304.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Dodhiawala, Paarth B., Bin Zhang, Andrew Baldys, et al. "797 Targeting the KRAS oncoprotein sensitizes pancreatic cancer to NK cell therapy." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0797.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Korbelik, Mladen, and Jinghai Sun. "Cancer treatment by photodynamic therapy combined with NK-cell-line-based adoptive immunotherapy." In BiOS '98 International Biomedical Optics Symposium, edited by Steven L. Jacques. SPIE, 1998. http://dx.doi.org/10.1117/12.308148.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Teng, Kun-Yu, Anthony Mansour, Zhu Zheng, et al. "Abstract LB154: A potent human CAR NK cell therapy directed against pancreatic cancer." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-lb154.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

LeSavage, Bauer, Everardo Hegewisch-Solloa, Stefanie Maurer, et al. "379 Functional characterization of expanded HSC-derived NK cells, an optimal source for allogeneic cell therapy." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0379.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Pellom, Samuel Troy, Anshu Malhotra, and Anil Shanker. "Abstract B107: Combination therapy of kidney cancer using bortezomib and natural killer (NK) cell transfer." In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 18-Sep 21, 2011; Washington, DC. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1055-9965.disp-11-b107.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "NK cell therapy"

1

Kohrt, Holbrook. Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada573699.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Kohrt, Holbrook. Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada595679.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!